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Presence of steatosis
1A Non-CC 19/43 (44.2%)
CC 2/17 (11.8%) p = 0.019
1B Non-CC 28/56 (50%)
CC 4/19 (21%) p = 0.034
2 Non-CC 7/15 (46%)
CC 4/20 (20%) n.s.
3 Non-CC 7/11 (63%)
CC 4/8 (50%) n.s.
n.s., not signiﬁcant.To the Editor:
We thank Drs. Toyoda and Kumada for raising the additional point
that HCV amino acid substitutions have also been demonstrated
to inﬂuence steatosis in the setting of HCV infection. In their study
of 122 patients, 85 of whom had a beneﬁcial IL28B genotype, Toy-
oda and Kumada found a trend for steatosis to be associated with
IL28B polymorphism, as only 22% of the patients with beneﬁcial
genotype have steatosis compared to 40% of patients with the less
beneﬁcial genotype. Thus, their r, though not signiﬁcant, is in line
with our study, where we likewise found a 25% and 27% higher
rate of steatosis in patients with the less beneﬁcial IL28B (‘‘non-
C/C’’ for rs12979860 or ‘‘non-T/T’’ for rs8999017) genotype in
two different cohorts of 145 and 180 patients, respectively. Simi-
lar to our and Toyoda and Kumada’s results, Cai et al. found an
association between the beneﬁcial IL28B genotype and lower ste-
atosis frequency [1]. However, a three center study by Trépo et al.
failed to ﬁnd a relevant association between IL28B genotype and
steatosis, according to their statement [2]. This latter paper, how-
ever, did not show the data, and therefore it cannot be assessed
whether the association was absent or only not signiﬁcant. Toy-
oda and Kumada’s study showed a similar trend for steatosis with
IL28B, whereby IL28B is associated with different mutations in the
core region, the HCV core mutation clearly shows a higher associ-
ation with steatosis.
In our article, we indicate that response to treatment in rela-
tion to steatosis seems unlikely to be explained by IL28B alone,
and though not speciﬁcally mentioned, IL28B is likely not solely
responsible for the association with steatosis. We had a small
cohort of 54 non-genotype 1 patients of whom 19 were genotype
3 and 35 were genotype 2. Despite the fact that steatosis tended
to be higher in ‘‘non-C/C’’ patients (4/20 [20%] vs. 7/15 [46%] in
genotype 2 patients and 4/8 [50%] vs. 7/11 [63%] in genotype 3
patients; Table 1) this was not signiﬁcant. However, the trend
was similar across genotypes. Furthermore, we have data on
genotype 1a and 1b in 60 and 75 patients from the ﬁbrosis study,
respectively. In concordance with the overall results, steatosis
was less frequently present in C/C genotype patients with both
HCV genotype 1a and 1b (Table 1).
A possible explanation lies in the virus itself as the authors
correctly point out with a focus on HCV’s core protein. Unfortu-
nately, we do not have the core antigen sequence of our patients.
A previous work by Jhaveri et al. suggested a role for amino acids
182 and 186 of the core protein, linking steatosis in vitro to stea-
tosis [3], but certainly amino acid 70 seems to be especially rele-
vant in genotype 1b infection. There is also some evidence
indicating that not all differences can be explained by viral core
sequence variation [4].Journal of Hepatology 20Conﬂict of interest
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